BOARD OF DIRECTORS
Elizabeth Cermak, MBA
Elizabeth (Liz) Cermak has over 35 years of experience in the Healthcare industry. Her diverse background spans Pharmaceuticals, Medical Devices, Consumer Healthcare Products and Health Management Services in both large and small companies. She currently serves as a Board Director for Clarus Therapeutics in Northbrook, IL, and is a Member of the Audit Committee. In addition, she served as a Board Director for SteadyMed Therapeutics (STDY) in San Ramon, CA until the company was purchased by United Therapeutics (UTHR) in August 2018. Previously, Ms. Cermak was Executive Vice President, Chief Commercial Officer and member of the Executive Committee of POZEN, Inc (POZN). Prior to that, Ms. Cermak served as the Worldwide Vice President of Global Marketing for Intimate Health Products, a segment of the Johnson & Johnson Consumer Health Care business (JNJ), and also served as the Vice President of the Women's Healthcare RX Franchise for now Janssen Pharmaceuticals. Ms. Cermak received a BA from Franklin & Marshall College and an MBA from Drexel University.
Julie Cherrington, PhD
Dr. Julie Cherrington is President and Chief Executive Officer of Arch Oncology, a clinical-stage immuno-oncology company. Dr Cherrington is a life science executive with more than 25 years of experience advancing drugs into and through clinical development and to commercialization. She has played a key role in the successful development of several FDA-approved products, including SUTENT™, Palladia™, Vistide™, Viread™, and Hepsera™.
Dr. Cherrington has previously served as President and CEO at Revitope, also an immuno-oncology company, at Zenith Epigenetics, an oncology focused bromodomain inhibitor company, and at Pathway Therapeutics, an oncology and inflammation company. Earlier in her career, she served as Vice President of Preclinical and Clinical Research at SUGEN, a Pharmacia/Pfizer company. Dr. Cherrington began her career at Gilead Sciences, where she held a range of positions of increasing responsibility. Dr. Cherrington currently serves on the Board of Directors at Mirati Therapeutics, a clinical-stage publicly-traded oncology company.
Dennis Liotta, PhD
Over the past two and a half decades Dr Dennis Liotta’s research has focused on the discovery and development of novel antiviral, anticancer and anti-inflammatory therapeutic agents. He is recognized as one of the world’s premier discoverers of novel therapeutics, having been one of the inventors associated with ten FDA approved therapeutics including Epivir, Combivir, Trizivir, Epzicom, Epivir-HBV, Emtriva, Truvada, Atripla, Complera and Stribid. In addition, he is the inventor of record for several clinically important antivirals, including Reverset, Racivir and Elvucitabine. He is also the lead inventor of Q-122, a safe, orally available clinical agent for controlling hot flashes in post-menopausal women. In the preclinical arena his research group has recently discovered the first potent, dual tropic (CCR5/CXCR4) HIV entry inhibitor. In addition, in his current role as Executive Director of the Emory Institute for Drug Development, Dennis oversaw the discovery and development of a novel nucleoside analogue, EIDD-2023, for treating hepatitis C infections.
Dennis has authored approximately 250 peer reviewed publications and is an inventor on 75 issued US patents. A company he founded, Pharmasset (acquired by Gilead Sciences) developed Sofosbuvir, which has become the first line therapy for treating (and perhaps curing) hepatitis C. In addition to QUE, he has founded numerous other companies including Altiris (drugs for stem cell mobilization and as potential treatments for a variety of cancers), Triangle Pharmaceuticals (developed emtricitabine and was subsequently acquired by Gilead Science), NeurOp (therapies for treating ischemic conditions, such as stroke) and DRIVE (Drug Innovation Ventures at Emory), a non-profit drug development company focused on the development of therapies for treating single stranded RNA virus infections, such as Dengue Fever, hepatitis C, influenza A and B, respiratory syncytial virus and various equine encephalitis viruses. DRIVE utilizes an innovative model that seeks to extract maximum value from therapeutic innovations discovered at Emory or elsewhere by efficiently advancing them into clinical trials.
Dean Moss, PhD
Dr Dean Moss has over 20 years' experience in science, academia, business, management and commercialisation in Australia, USA and the UK. He has been managing director or senior business development executive of several health and biotech companies worldwide, including Agen Biomedical, Launch Diagnostics, Amrad ICT, Amrad Biotech, and United Drug. He established his own start-up business in the UK, York Medical Technologies.
Prior to moving into the commercial world, Dean was principal R&D scientist at Agen Biomedical. He also worked as an NH&MRC research scientist at the Princess Alexandra Hospital, the Royal Brisbane Hospital and the Queensland Institute of Medical Research. He is a recipient of the Campion-Ma-Playoust Memorial Award for Medical Research.
Dean is a board member of Coridon Pty Ltd, Bio Energy Solutions Pty Ltd (Chairman), Dendright Pty Ltd (Chairman) and Q-Pharm Pty Ltd, and has contributed to raising more than $20m in venture capital investment.
Chris Nave, PhD, MBA
Chris is a founding partner of Brandon Capital Partners and Principal Executive of the Medical Research Commercialisation Fund. In addition to OccuRx, Chris currently holds directorships with Spinifex Pharmaceuticals, Osprey Medical Inc., PolyActiva Pty Ltd, Global Kinetics Corporation and Otifex Therapeutics Pty Ltd. Chris previously was Director of Commercialisation at the Baker IDI Heart and Diabetes Institute, Melbourne, Australia. He was responsible for the commercialisation of technologies developed at the Baker and the Alfred Hospital, including the management of local and international spinout companies.
Prior to this, Chris was the Manager of the Biotechnology Team at Melbourne Ventures, the commercialisation company of the University of Melbourne. Concurrently during this period, he was an Investment Manager for, and on the investment committee of, Uniseed Pty Ltd, a $60 million pre-seed fund. Chris has international experience with Leiras Pharmaceuticals in Finland, a wholly owned subsidiary of Schering AG, working for their Business Development group. He successfully moved companies to the US, securing investment from US investors for these companies. Past directorships have seen Chris involved directly in the management, fundraising, and successful spinout of various companies in the life sciences industry. Chris was also Chairperson of Fibrotech Therapeutics at the time of its successful sale to Shire. In 2014, he was awarded the AusBiotech Johnson & Johnson Industry Leadership Award.
Chris has a first-class Honours degree in Science and a PhD in Endocrinology and Physiology from the University of Melbourne and he has completed the Private Equity and Venture Capital Program at Harvard Business School, Boston, MA
John P. Richard, MBA
John is Head of Corporate Development and a co-founder of Mereo BioPharma Group, plc.
He has significant corporate, operational and transactional experience, having served in various executive, director and advisory roles throughout his career. He is a board member of Vaxart Incorporated, Phase4 Partners, QUE Oncology and Catalyst Biosciences.
Previously, he was Executive VP Business Development at SEQUUS, where he was responsible for negotiating SEQUUS’ acquisition by ALZA. John also headed business development for VIVUS and Genome Therapeutics; where he established numerous alliances.
John received his M.B.A. from Harvard Business School and his B.S. from Stanford University.